Objective: To examine the effects of ghrelin on appetite and energy expenditure in lean, obese and postgastrectomy subjects. Design: A randomized, double-blind, placebo-controlled study. Patients: Nine lean subjects (mean body mass index (BMI) 23.5±3 kg/m 2 ) and nine morbidly obese subjects (mean BMI 51.4 ± 10 kg/m 2 ) and eight postgastrectomy subjects (mean BMI 22.4 ± 1.0 kg/m 2 ). Interventions: Subjects were infused with either intravenous ghrelin (5 pmol kg À1 min À1 ) or saline over 270 min. They were given a fixed energy breakfast followed by a free buffet lunch towards the end of the infusion. Main outcome measures: Visual analogue scales were used to record hunger and energy expenditure was measured by indirect calorimetry. Results: Ghrelin increased energy intake at the buffet lunch in lean subjects (a 41% increase, Po0.01) and obese subjects (35% increase, P ¼ 0.04) but not in postgastrectomy subjects. Lean subjects showed a characteristic preprandial rise and postprandial fall in hunger scores, which was exaggerated by ghrelin infusion. Obese subjects showed little variation in hunger scores, but a 'lean-type' pattern was restored when given exogenous ghrelin. Ghrelin had no effect on resting metabolic rate but did increase respiratory quotient (RQ) in obese subjects. Ghrelin also increased RQ variability over time in all three groups (ANOVA, Po0.001). Conclusions: Hunger scores are abnormal in the obese, perhaps because of impaired ghrelin secretion. The effect of ghrelin in restoring normal hunger profiles in the obese suggests causality, confirming an important role in eating behaviour. Ghrelin also increases RQ in obese humans and increased RQ variability in all groups. This suggests that ghrelin regulates substrate utilization and may promote metabolic flexibility.
Introduction
Ghrelin was discovered in 1999 as the natural ligand of the growth hormone secretagogue receptor, and it strongly stimulates growth hormone secretion. 1 In addition, it was also found to increase food intake when given peripherally to rodents and human subjects. [2] [3] [4] Twenty-four hour serum profiles in humans given three meals a day showed that circulating ghrelin increases before a meal, and decreases afterwards. 5 Furthermore, when subjects voluntarily requested meals without time cues, ghrelin was found to rise in anticipation of the coming meal and correlated with hunger scores. 6 These studies suggest that ghrelin acts as a meal initiator in humans and that ghrelin and perceived hunger are closely linked. Ghrelin also influences energy expenditure; rodent studies have shown that ghrelin increases respiratory quotient (RQ) but this has not been replicated in humans. 3, 7 Obese subjects are known to have low circulating ghrelin levels, and ghrelin levels increase with subsequent weight loss. This implies that ghrelin is involved in long-term weight regulation. However, obese subjects do not have the same ghrelin profiles as lean subjects, and there is an attenuated suppression of ghrelin release after a meal in the obese state. 8 Although numerous studies have commented on abnormal eating patterns in the obese, there are little published data comparing hunger profiles between lean and obese subjects around a fixed energy meal. It is of interest to determine whether the abnormal ghrelin profiles around a meal in the obese are reflected by abnormal hunger profiles in these subjects. Similarly, obese subjects are known to have impaired postprandial thermogenesis and whether this is related to low ghrelin levels is not known. 9 Two-thirds of ghrelin production is from the stomach and subjects who have undergone a gastrectomy have significantly reduced ghrelin levels. 10, 11 Hence, these subjects provide us with a human model with a marked reduction in circulating ghrelin levels. Appetite and energy intake has previously been described 12 but to our knowledge energy expenditure has not been investigated in subjects who have undergone gastrectomy. Our aim was therefore to examine the effects of ghrelin on appetite and energy expenditure in three groups of subjectsFlean, morbidly obese and postgastrectomyFthus allowing us to investigate two different models with reduced circulating ghrelin levels in comparison with a control population.
Subjects and methods
Volunteers were recruited by advertisement, from a local weight management clinic and from a surgical database. The study was approved by the South Sefton Research Ethics Committee (project registration number EC.05.03) and was performed in accordance with the principles of the Declaration of Helsinki. Volunteers gave written informed consent and had a normal physical examination and electrocardiogram. Urea and electrolytes and fasting glucose were normal in all subjects.
Subjects
We studied nine healthy volunteers aged 25- . Subject numbers were based on recruitment and previous published work showing a minimum of seven subjects were needed to show clear differences in appetite and energy intake. 13 Obesity was defined as BMI430 kg/m 2 according to the criteria of the World Health
Organisation and the International Obesity Task Force. All gastrectomy subjects underwent total gastrectomy for gastric carcinoma at least 12 months previously and were in remission (none had any evidence of recurrence by gastroscopy within the past 12 months). All subjects had a truncal vagotomy as part of the procedure. The mean time between surgery and the study was 6.7±1.4 years (mean±s.e.m.). None of the subjects had any form of chemotherapy/ radiotherapy within the past 3 years. Gastrectomy subjects with significant bile reflux (assessed by clinical history and gastroscopy) and symptoms of dumping syndrome were excluded. Subjects in all groups with ischaemic heart disease, type 2 diabetes and those aged over 75 years were excluded. Any drugs deemed to affect appetite were stopped for 2 weeks before the study.
Protocol
The protocol is summarized in Figure 1 . Subjects were asked to fast and drink only water from 2100 hours on the night before the study, and to refrain from alcohol or strenuous exercise in the 24 h preceding the study day. Each subject was studied on two occasions and received two infusions À0.9% saline and ghrelin (5 pmol kg À1 min
À1
), in a randomized, double-blind, crossover design. The dose of 5 pmol kg À1 min À1 was chosen, as previous studies have
shown an intravenous infusion of ghrelin at this dose leads to a significant increase in food intake in lean and moderately obese subjects.
2,3
Human ghrelin was supplied in the acylated (octanoylated) form and produced by Clinalfa Products, Merck Biosciences AG, Laufelfingen, Switzerland.
Subjects attended at 0730 hours on each study day. Two intravenous cannulae were inserted into veins in both forearms. After venous cannulation, the subjects relaxed for 30 min before the start of the study protocol. The infusion was started at 0830 hours (t ¼ 0) and lasted for 270 min. Previous studies have shown that plasma ghrelin levels during an infusion reach a steady state within 60 min, 3 Ghrelin restores hunger profiles in obese MSB Huda et al hence a fixed energy breakfast was given to all subjects at 60 min from the start of the infusion. This consisted of 40 g cornflakes, 250 ml whole milk, 3.5 g sugar (1 sachet) and 100 ml fresh orange juice (1550 kJ (368 kcal), 62% carbohydrate, 13% protein and 25% fat). This meal was chosen, as it represents a typical European style breakfast, which was palatable to most tastes and was a suitable meal for the timing of the study. They were subsequently offered a free buffet lunch at 1230 hours (240 min after starting the infusion). The items offered at the buffet lunch were consistent between subjects, and were designed to be acceptable to a wide range of palates. The infusion was stopped at 1300 hours after the buffet lunch was completed.
The food was weighed pre-and postprandially by a blinded investigator. The purpose of providing a fixed meal and a buffet meal was to be able to compare responses to a fixed energy meal, and then to subsequently assess food intake during the infusion. Blood samples were taken at baseline, 30, 60, 75, 90, 105, 120 min and then hourly until the end of the study. The study was completed at 1630 hours. Samples were collected into plastic EDTA tubes containing 0.07 mg aprotonin (500 Kallikrein Inactivator Units (KIU)), centrifuged immediately and then stored at À80 1C until assayed. At each sampling point subjects also completed a visual analogue scale (VAS) rating hunger and satiety (possible scores 0-100 mm). VAS were measured by an investigator blinded to study group and infusion data. Energy expenditure and RQ was measured by indirect calorimetry (Deltatrac II) at hourly intervals throughout the study. Subjects were supine and relaxed during indirect calorimetry and measurements were averaged over a 20 min sampling period. Resting metabolic rate (RMR) was calculated using the formula ((5.5 Â VO 2 ) þ (1.76 Â VCO 2 )-25.87) and RQ using the formula (VCO 2 /VO 2 ).
Assays
Plasma total (acylated and deacylated) ghrelin was determined in duplicate by a commercially available radioimmunoassay (Phoenix Pharmaceuticals, Belmont, CA, USA). Intra-and interassay coefficients were 7.3 and 9.5%, respectively.
Statistical analysis
The Statistical Package for the Social Sciences version 13.0 (SPSS, Chicago, IL, USA) was used for data analysis. Mean values are expressed as geometric mean ± s.e.m. Comparisons between groups were performed using paired t-tests or the equivalent non-parametric tests (Mann-Whitney or Wilcoxon signed ranks). Within-group and group interactions with time were analysed using ANOVA for repeated measures. Where violations in parametric assumptions were found within the data set, the within group and group interactions were measured using a multivariate ANOVA (MANOVA). If an overall interaction was found using ANOVA (or MANOVA) then post hoc tests (either t-tests or the above non-parametric tests) were done to identify significant differences at individual time points. Analysis of covariance (ANCOVA) was used to correct for body composition when examining differences in RMR. Total area under the curve (AUC) was calculated using the trapezoid rule. Statistical association was calculated using Pearson (r) correlation coefficients Two tailed P values were considered significant when Po0.05.
Results

Baseline characteristics
Baseline characteristics are summarized in Table 1 . The lean and obese groups were well matched for age and gender, but the gastrectomy group was significantly older (39.2 ± 4.2 vs 60.1 ± 4.5, Po0.05). However no significant correlation between age and fasting ghrelin was found in any of the three groups. The mean BMI in the obese group (51.4 ± 3.4 kg/m 2 ) was significantly higher than in the lean group (22.3±0.9 kg/m 2 ). Weight, waist circumference and body fat percentage were also higher in the obese group. There was no significant difference in BMI, weight, waist circumference and body fat percentage in the gastrectomy group compared to the lean group.
Plasma ghrelin
Fasting ghrelin levels were significantly lower in the obese group compared to the lean group (lean 762.1 ± 71.1 pg/ml Ghrelin restores hunger profiles in obese MSB Huda et al f(5,35) ¼ 4.7 P ¼ 0.02). Paired t-tests were used post hoc to compare each time point with the baseline and significant differences are identified in Figure 2a . Plasma ghrelin levels during the ghrelin infusion reached steady state after 60 min (Figure 2b ). There was no significant difference between the mean steady state plasma ghrelin or the AUC in any of the three groups (Table 1) . It was noted that the obese group appeared to have higher plasma ghrelin levels at 180 min after the start of the infusion than the other two groups (Figure 2b ), but this did not reach statistical significance.
Energy intake
Energy intake during the buffet lunch was increased in lean subjects by 41 ± 14% on the ghrelin infusion day compared with the saline infusion visit (3707 ± 414 kJ vs 2626 ± 238 kJ, P ¼ 0.008). Obese subjects also increased their energy intake significantly by 35±14% during the ghrelin infusion (3873 ± 575 kJ vs saline 2867 ± 501 kJ, P ¼ 0.04). Gastrectomy subjects, however, did not increase energy intake during the ghrelin infusion (1923±226kJ v saline 1764±205kJ, P ¼ 0.4). During the saline condition, there was no difference in energy intake between lean and obese (P ¼ 0.7) but there was a significant difference between lean and gastrectomy (P ¼ 0.02). This is shown in Figure 3 .
Effects on appetite
Lean subjects showed a characteristic preprandial rise and postprandial fall in hunger scores with each meal during the saline infusion. When ghrelin was given, they showed a similar but exaggerated pattern (Figure 4a ). Obese subjects have a flattened hunger profile that does not significantly change from baseline during the saline infusion; but when ghrelin was given, a marked preprandial rise and postprandial fall in hunger scores is observed (Figure 4b ).
There was a significant overall interaction between hunger, hormone and group (MANOVA f(12,5) ¼ 3.95, P ¼ 0.035) and hunger changed significantly with time (MANOVA f(12,5) ¼ 5.75, P ¼ 0.033). During the saline infusion there was a highly significant difference between lean and obese hunger scores (f(12,96) ¼ 6.61, Po0.001) at time points 30 (P ¼ 0.037), 60 (P ¼ 0.012), 75 (P ¼ 0.017), 105 (P ¼ 0.012), 120 (P ¼ 0.001), 180 (P ¼ 0.003), 240 (P ¼ 0.001). However, when given ghrelin there was no significant difference between the lean and obese groups (f(12,5) ¼ 2.62, P ¼ 0.15).This shows that statistically, ghrelin restores a lean pattern in the obese.
Gastrectomy subjects showed a similar preprandial rise and postprandial fall in hunger scores to lean controls and Energy intake (kJ) saline ghrelin * * Figure 3 Mean energy intake at a buffet meal in lean, obese and gastrectomy groups. *Significant increase in energy intake Po0.05.
Ghrelin restores hunger profiles in obese MSB Huda et al there was no significant difference between the groups (ANOVA P ¼ 0.53). There was also no significant effect of ghrelin on hunger scores (Figure 4c ). In contrast to lean and obese subjects, gastrectomy subjects showed a gradual rise in hunger scores after initially decreasing after the buffet lunch. Figures 5a-c show the satiety VAS scores in the three groups. The lean and gastrectomy groups had similar temporal profiles with satiety increasing after each meal (ANOVA P ¼ 0.8), but in neither group was satiety significantly altered by the ghrelin infusion. The obese group, though showing a similar pattern to the other two groups during the saline infusion (ANOVA P ¼ 0.9), showed a significant reduction in satiety VAS scores (ANOVA Ghrelin restores hunger profiles in obese MSB Huda et al Po0.05) during the ghrelin infusion, while maintaining the same temporal profile. After the ghrelin infusion was completed, however, the satiety scores return to normal and the lines representing the ghrelin and saline infusions converge.
Effects on energy expenditure RMR was not significantly different between the three groups when corrected for total fat mass (ANCOVA f(16,30) ¼ 1.5, P ¼ 0.16) and there was no significant effect of ghrelin infusion on RMR (ANCOVA f(2,21) ¼ 0.32, P ¼ 0.73). This data is shown in Table 2 . By contrast, ghrelin had a significant overall effect on RQ with pooled data from all three groups (ANOVA f(1,21) ¼ 5.6 P ¼ 0.03). Preprandial RQ (that is, before the fixed energy breakfast) was also not altered by the ghrelin infusion in any of the three groups. Postprandial (after the fixed energy breakfast) RQ was increased with the ghrelin infusion in lean subjects (0.92 ± 0.03 vs 0.97 ± 0.03) but did not reach statistical significance (P ¼ 0.13). Although, there was a significant overall difference in RQ in obese subjects (ANOVA f(8,62) ¼ 2.81, P ¼ 0.01) between the ghrelin and saline conditions, subsequent post hoc tests showed that only postprandial RQ (after the fixed energy breakfast) was significantly higher during the ghrelin infusion (0.86 ± 0.01 vs 0.93 ± 0.03, P ¼ 0.03). Figure 6a shows the characteristic pattern of postprandial rise in RQ in lean subjects. Lean subjects have a significant rise in RQ after the fixed energy meal (P ¼ 0.01) on both study days. In contrast, obese subjects have no significant postprandial RQ rise (P ¼ 0.1) during the saline infusion, but during the ghrelin infusion there is a significant postprandial rise in RQ (P ¼ 0.03) and a similar temporal profile to the lean subjects is restored (Figure 6b) .
Gastrectomy subjects did not show any significant change in RMR or RQ between ghrelin and saline infusions, using AUC calculations and comparing pre-and postprandial RQ. The temporal profile of RQ in response to meals (Figure 6c ) and RMR during the saline infusion were not significantly different to that of lean subjects.
Of interest, however, there was an overall significant effect of ghrelin on displacement from baseline values compared with the saline infusion (ANOVA f(8,168) ¼ 6.2, Po0.001). This suggests that peripheral ghrelin increased RQ variability over time in all the groups (including the gastrectomy subjects). Ghrelin restores hunger profiles in obese MSB Huda et al
Discussion
Our study examined the effects of exogenous ghrelin on appetite and energy expenditure in lean, morbidly obese and postgastrectomy subjects. We have confirmed previous studies showing that ghrelin increases hunger scores and food intake in healthy controls. 3 Druce et al. 2 have shown that ghrelin also increases food intake and hunger scores in moderately obese subjects with a mean BMI of 31.9 kg/m 2 . However, our study is the first report confirming that morbidly obese subjects with a mean BMI of 51.4 kg/m 2 are also sensitive to the effects of ghrelin on appetite and food intake.
We have shown that morbidly obese subjects have an altered pattern of hunger scores around a fixed energy meal compared to lean controls. Morbidly obese subjects, therefore, do not report a preprandial rise and postprandial fall in hunger as reported by lean controls. There have been several reports of abnormal eating behaviours in obesity, 14 but we found only one recent report comparing VAS scores around a fixed energy meal between lean and obese subjects. 15 Interestingly, the investigators looked at appetite in different groups of morbidly obese subjects and in contrast to our data, found clear oscillations of hunger and satiety with meals. However, their subject group had a mean BMI of 41.3±0.9 compared with our subject group who had a mean BMI of 51.4 ± 3. It is plausible that our group represents a 'super obese' category of obesity and may show an altogether different pattern of VAS scores around a fixed meal. The lack of an identifiable preprandial peak and postprandial trough in hunger in obese subjects may be associated with the abnormal eating patterns often seen in these subjects.
14 However, when given exogenous ghrelin a characteristic 'lean-type' pattern of hunger is restored in obese subjects. It is known that plasma ghrelin levels are lower in obese subjects and that they do not show the same suppression of ghrelin release with meals. 8, 16 Our study confirms these findings in morbidly obese subjects and this appears to be reflected by their reported hunger scores. Therefore, administration of ghrelin to subjects with decreased circulating ghrelin restores a normal physiological pattern of hunger. Of course, hunger may be under-reported in obese subjects but in the subjects studied here, when given ghrelin, hunger appears to be reported appropriately.
Indeed, ghrelin appears to be a potent stimulator of hunger in this group as the hunger scores are higher at each time point compared to the saline infusion day. Hence, low ghrelin levels in obesity which would initially appear to be advantageous may actually be maladaptive and propagate abnormal eating patterns that is, the constant low levels of ghrelin and flattened hormone profiles around traditional mealtimes may be a factor in the continuous 'grazing' pattern that is seen in obese subjects. The fact that obese subjects respond so markedly to exogenous ghrelin is supportive of this and again suggests that ghrelin and hunger are linked closely in these subjects. However, we accept that the regulation of appetite and food intake is complex and it is unlikely that changes in the plasma levels of any single hormone or peptide would alone account for the multitude of physiological and psychological changes that often accompany morbid obesity.
Satiety was also lower in obese subjects when given ghrelin but did not change in lean controls or gastrectomy subjects. The reason for this is not clear and it may be that obese subjects report satiety in a different way to the other groups. They may have found the fixed energy meal less satiating than the other groups, 17 although they did not report this in the saline condition (Figure 5a ). Indeed, though peptide YY (PYY) and glucagon-like-peptide-1 (GLP-1) are reported to be lower in obese subjects 18, 19 our subjects showed a very similar satiety profile to lean subjects (Figures 5a and b) , despite an abnormal hunger pattern. Specifically, the temporal pattern of satiety in obese subjects (Figure 5b ) remains unaltered during the ghrelin infusion but significantly diminished, and quickly returns to normal after the infusion ends. Alternatively, there may be a hormonal explanation for this; is it is possible that ghrelin has an effect on short-term satiety signals in the obese? Le Roux et al. did not find any effects of exogenous ghrelin on the satiety hormones GLP-1 and PYY in healthy controls and vagotomized subjects but it is noteworthy that they did not examine the obese condition.
12
Similar to other studies we have shown that gastrectomy subjects have low plasma ghrelin levels. 20 Pekic et al.
21
recently showed that unlike healthy subjects, gastrectomy subjects do not show a suppression of plasma ghrelin release after an oral glucose load. In keeping with their findings, our gastrectomy subjects had a flattened ghrelin response to a fixed calorie meal and plasma ghrelin did not vary significantly from baseline. It is also known that ghrelin has acute effects on glucose disposal and enhances growth hormone release in gastrectomized subjects, suggesting these subjects are sensitive to the acute metabolic effects of ghrelin. 22, 23 Subjects who have had a previous total gastrectomy often complain of reduced appetite and have difficulty with weight gain after their operation. 24, 25 This may be secondary to low plasma ghrelin levels that follow gastrectomy, and replacement of ghrelin in these patients would seem an attractive therapeutic option. 26 Our study however shows that gastrectomy subjects do not show a significant increase in appetite and energy intake during a ghrelin infusion. We initially postulated that this lack of response to peripheral ghrelin was due to truncal vagotomy that was performed in all of our subjects. Indeed, previous reports in both rodents and humans had suggested that vagotomy abolished the effects of peripheral ghrelin on feeding. 12, 27 However, this has recently been questioned by Arnold et al. 28 who found that gut vagal afferents were not necessary for the effects of ghrelin on feeding. It is possible that there is a downregulation in central GHS-R/ghrelin receptors following total gastrectomy, but to our knowledge this has not been Ghrelin restores hunger profiles in obese MSB Huda et al examined experimentally. It is also of interest to note that during the saline condition, gastrectomy hunger and satiety profiles were similar to healthy controls. As these subjects have low circulating ghrelin, this questions the association between ghrelin and perceived hunger in these subjects. Despite describing similar hunger and satiety and with ample time for consumption, they ate significantly less at the buffet meal than healthy controls. Clearly, factors other than appetite and circulating ghrelin influence energy intake in these subjects; these have been described in previous studies and include psychological issues, feelings of nausea with certain foods and altered satiety. 29, 30 In agreement with rodent studies, which have shown that ghrelin increases RQ, 7, 31 we have shown that ghrelin has an overall effect on RQ and increases postprandial RQ in obese humans. Ghrelin also appeared to increase postprandial RQ in healthy controls but this did not reach statistical significance. Interestingly, obese subjects do not have a significant postprandial rise in RQ compared to lean subjects during the saline infusion. Decreased RQ is indicative of greater fat utilization and this is in keeping with other studies which suggest that postprandial substrate utilization may be altered in obesity. 32 The overall increase in RQ seen during the ghrelin infusion in healthy and obese subjects implies that in human subjects, as in rodents, ghrelin promotes adiposity. Another interesting finding was that peripheral ghrelin has an overall effect on RQ variability over time compared with the saline condition. This effect was present in all three groups, despite the apparent minimal effect on the gastrectomy group. It is plausible that ghrelin at pharmacological doses promotes greater oscillations in meal-related substrate utilization. This has not been widely reported in the literature, and it is intriguing that different conclusions were found recently in ghrelin receptor knockout mice; they appeared to have increased RQ variability compared to controls. 33 Therefore, in our study ghrelin may have restored a 'lean' temporal pattern of substrate utilization in both obese and gastrectomy subjects simply by promoting greater RQ variability with meals.
The main limitation of this study was that the ghrelin infusion achieved supraphysiological plasma levels of total ghrelin. These levels were approximately 5-to 10-fold higher than physiological levels after a meal. As we measured total ghrelin and infused acylated ghrelin, the levels of acylated ghrelin may be underestimated compared to physiological release; this can only be speculated, as we did not measure acylated ghrelin. In addition, it is known that acylated ghrelin makes up only around 10% of circulating total ghrelin, and the administration of supraphysiological doses of acylated ghrelin may have overtaken the influence of nonacylated ghrelin. 34, 35 In conclusion, these findings suggest that ghrelin increases hunger and food intake and affects substrate utilization in lean and morbidly obese subjects but not in gastrectomy subjects. However, there maybe subtle effects of peripheral ghrelin by increasing RQ variability in all three groups. Administration of ghrelin in obese subjects restores 'leantype' patterns of appetite and substrate utilization, although this should be seen in the context of an overall increase in hunger and calorie intake in the obese.
